Abstract Number: 1562 • ACR Convergence 2022
Validation of Behçet’s Disease Overall Damage Index (BODI) for Retrospective Studies and a Proposal for Modification
Background/Purpose: Damage accrual in Behçet syndrome (BS) may progress over the years and an index that can be scored using retrospective data may be useful…Abstract Number: 1602 • ACR Convergence 2022
Fibroblast Activation Protein (FAP) PET-CT for Depicting Inflammatory Joint Damage in Patients with Psoriatic Arthritis
Background/Purpose: Psoriatic arthritis (PsA) is characterized by substantial mesenchymal tissue activation in the context of inflammation leading to structural damage. Measuring mesenchymal tissue activation in…Abstract Number: 0071 • ACR Convergence 2021
Damage Accrual Measured by DIAPS in Antiphospholipid Antibody (aPL)-positive Patients: Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Background/Purpose: Damage Index in APS (DIAPS) is a scoring system developed to assess long-term damage in thrombotic primary antiphospholipid syndrome (PAPS), which also correlates with…Abstract Number: 0080 • ACR Convergence 2021
One Point Increase in the Initial Damage as Measured by the Damage Index for Antiphospholipid Syndrome Predicts Mortality in a Multi-Ethnic Group of Thrombotic Antiphospholipid Syndrome Patients
Background/Purpose: The chronic and recurrent nature of antiphospholipid syndrome (APS) leads to damage accrual that impairs long-term functional status and survival. The Damage Index for…Abstract Number: 0388 • ACR Convergence 2021
Prediction Tool for Damage Accrual Trajectory in Incident Systemic Sclerosis
Background/Purpose: Systemic sclerosis (SSc) is a systemic autoimmune disease associated with the accrual of organ damage over time, which can be measured using the Scleroderma…Abstract Number: 0878 • ACR Convergence 2021
Investigating the Neutrophil to Lymphocyte Ratio as a Marker of SLE Disease Activity, Health-Related Quality of Life and Depression
Background/Purpose: The need for readily available markers of SLE activity has led to the evaluation of laboratory parameters, such as the neutrophil to lymphocyte ratio…Abstract Number: 1298 • ACR Convergence 2020
Lupus Damage Free-Survival by Age at Diagnosis: A Retrospective Incident Lupus Cohort
Background/Purpose: While medical comorbidities increase with age, younger age at onset of Systemic Lupus Erythematosus (SLE) has been associated with greater risk of some types…Abstract Number: 1393 • ACR Convergence 2020
Systemic Sclerosis: Subclinical Aterosclerosis and Morbimortality
Background/Purpose: Rheumatic diseases are associated with accelerated atherosclerosis, and an increase in cardiovascular morbidity and mortality. This process is mediated by classic cardiovascular risk factors…Abstract Number: 2036 • ACR Convergence 2020
Damage Trajectories in Systemic Sclerosis Using Group-Based Trajectory Modeling
Background/Purpose: Systemic sclerosis (SSc) is a rare systemic autoimmune disease associated with a high mortality and characterized by the accrual of organ damage over time.…Abstract Number: 0267 • ACR Convergence 2020
Gastrointestinal Disease in SLE: Does It Indicate a Worse Prognosis?
Background/Purpose: To describe the GI manifestations of SLE in the RELESSER (Registry of Systemic Lupus Erythematosus Patients of the Spanish Society of Rheumatology) cohort and…Abstract Number: 0271 • ACR Convergence 2020
External Validation of the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) as a Predictor of Mortality and Organ Damage Accrual in Systemic Lupus Erythematosus
Background/Purpose: Using data from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort, a frailty index (FI) was recently developed as a measure of susceptibility…Abstract Number: 0853 • ACR Convergence 2020
Gradual Glucocorticoid Withdrawal Is Safe in Clinically Quiescent Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) patients are usually treated with glucocorticoids even during periods of clinically quiescent disease. A recent study showed that abrupt glucocorticoid…Abstract Number: 0864 • ACR Convergence 2020
Effect of Cumulative Hydroxychloroquine Dose on Prevention of Damage Progression in Patients with Systemic Lupus Erythematosus
Background/Purpose: Hydroxychloroquine (HCQ) has demonstrated a wide array of beneficial effects in patients with systemic lupus erythematosus (SLE), with regard to disease activity, flare rates,…Abstract Number: 1021 • ACR Convergence 2020
Organ Damage in Systemic Lupus Erythematosus Is Attributable More to Comorbidity (Hypertension) and Less to Socioeconomic Status
Background/Purpose: Multiple variables are known to contribute to development of organ damage in SLE patients, including prednisone use and ethnicity. The aim of this study…Abstract Number: 1167 • ACR Convergence 2020
Capturing the Range of Disease Involvement in Localized Scleroderma: The Total Morbidity Score
Background/Purpose: Localized scleroderma (LS) is a chronic inflammatory and fibrosing disease that causes both cutaneous and extracutaneous (EC) damage. EC involvement (ECI) is common in juvenile…